1. Home
  2. PRAX vs SNEX Comparison

PRAX vs SNEX Comparison

Compare PRAX & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$259.15

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo StoneX Group Inc.

SNEX

StoneX Group Inc.

HOLD

Current Price

$56.16

Market Cap

7.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
SNEX
Founded
2015
1924
Country
United States
United States
Employees
N/A
5400
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
7.4B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
PRAX
SNEX
Price
$259.15
$56.16
Analyst Decision
Strong Buy
Buy
Analyst Count
21
3
Target Price
★ $650.00
$133.28
AVG Volume (30 Days)
498.9K
★ 945.0K
Earning Date
11-04-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 3.49
Revenue
N/A
★ $132,378,200,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$39,256.17
N/A
P/E Ratio
★ N/A
$16.39
Revenue Growth
N/A
★ 32.53
52 Week Low
$154.46
$56.46
52 Week High
$392.70
$141.99

Technical Indicators

Market Signals
Indicator
PRAX
SNEX
Relative Strength Index (RSI) 38.80 26.51
Support Level $238.77 N/A
Resistance Level $356.02 $71.09
Average True Range (ATR) 12.63 2.09
MACD -0.52 -0.52
Stochastic Oscillator 35.55 1.18

Price Performance

Historical Comparison
PRAX
SNEX

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About SNEX StoneX Group Inc.

StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.

Share on Social Networks: